Semaglutide's highest dose for weight loss — what the evidence says

Why did the highest semaglutide dose for weight loss change in 2026?

For several years, 2.4mg was the standard maintenance dose for Wegovy, the dose used in the landmark STEP 1 trial, which showed an average weight reduction of around 15% over 68 weeks. That was a meaningful result, but researchers kept asking whether a higher dose could close the gap with newer dual-agonist medicines.

The answer came in two steps. First, in January 2026, the MHRA authorised a 7.2mg maintenance dose delivered across three 2.4mg pens each week. Then, on 14 April 2026, a dedicated single-dose 7.2mg pen was approved, one injection, pre-set, with an auto-dosing mechanism and a covered needle that locks after use. That pen is what most people mean when they ask about the highest dose today. You can read the MHRA's announcement on GOV.UK for the full detail.

The 7.2mg pen is licensed for adults with a BMI of 30 or above, used alongside a reduced-calorie diet and increased physical activity. It is not licensed for the cardiovascular indication or for BMI below 30. Your prescriber confirms whether the highest dose is appropriate for your situation; the pen format and dose availability are confirmed at the point of consultation, not before.

What does the evidence show at 7.2mg, and how does it compare to 2.4mg?

Trial data for the 7.2mg dose reported around 20.7% average weight loss over 72 weeks. If you want to understand how that compares to earlier options, our page on semaglutide dose for weight loss explains how the different dose levels relate to the clinical evidence. The dosing schedule to reach 7.2mg follows the same patient principle as the rest of the Wegovy dose progression: slow escalation to manage side effects. You begin at 0.25mg, move to 0.5mg, then 1.0mg, 1.7mg, 2.4mg, and only then (if clinically appropriate) continue upward. Each step takes roughly four weeks. The MHRA's NHS medicines page for semaglutide sets out the general profile of the medicine for patients. Rushing the schedule doesn't improve results; the gastrointestinal side effects (nausea, vomiting, diarrhoea are the most common) tend to be worse when doses are increased before the body has adjusted.

One practical note on storage: the 7.2mg pen, like all Wegovy formats, needs to be kept refrigerated between 2°C and 8°C until you're ready to use it, many people keep it in the fridge door. The exact room-temperature window if you're caught without refrigeration is in the Patient Information Leaflet, and that's the document to follow, not a general online summary.

Who can actually reach the 7.2mg dose through a prescriber?

Eligibility for semaglutide weight-loss treatment starts with a BMI of 30 or above, or 27 to 29.9 alongside at least one weight-related condition such as high blood pressure, high cholesterol, type 2 diabetes or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. Those are the entry criteria for starting treatment, they are not the same as the criteria for reaching the maximum dose.

To move to 7.2mg specifically, a prescriber needs to see that you have tolerated lower doses and that continuing upward is clinically appropriate. If you are currently on the step below and want to understand what comes next, our page covering the semaglutide 2 mg dose for weight loss sets out what to expect at that stage and how escalation decisions are made. Transfer patients asking about the highest dose of semaglutide will be asked to provide evidence of their current treatment and response before any increase is considered. That's not bureaucracy; it's the clinical standard that keeps dose escalation safe.

On the NHS, semaglutide is available through specialist weight management services under NICE guidance (TA875), which carries its own eligibility thresholds and a maximum treatment duration of two years. Waiting lists for those services can be long. Private treatment through a regulated online pharmacy (one you can verify on the GPhC pharmacy register) is the alternative for people who meet the clinical criteria but don't want to wait or don't qualify for the NHS route. Pricing context for private treatment is worth understanding; the Wegovy price comparison page covers what different providers typically include.

What side effects are more common at higher semaglutide doses?

Higher doses don't introduce entirely new side effects, they tend to amplify the gastrointestinal ones that most people already know about. Nausea is the most frequently reported, followed by vomiting, diarrhoea, constipation and reflux. These are usually most noticeable after a dose increase and tend to settle within a week or two as the body adjusts.

One side effect that warrants specific attention at any dose is pancreatitis. In January 2026, the MHRA issued a Drug Safety Update highlighting acute pancreatitis as an infrequent but potentially serious risk with GLP-1 medicines: severe stomach pain, especially pain that spreads to the back, with or without vomiting, needs prompt medical attention rather than a wait-and-see approach. That update applies across the semaglutide dose range.

If you're approaching the question of whether the highest dose is right for you, our frequently asked questions cover a range of practical concerns that come up in consultations. And if you'd like to understand more about how Wegovy fits into the broader landscape of weight-loss treatments, the weight-loss treatments overview gives a grounded starting point. Speak to our prescribers to find out whether you're a good candidate for semaglutide, and which dose might be appropriate for you.